Vincent Ossipow
Patrimonio netto: 3 M $ in data 31/05/2026
Patrimonio netto: 3 M $ in data 31/05/2026
Vincent Ossipow was the founder of Omega Alpha SPAC, founded in 2020, serving as Chief Scientific Officer.
Current jobs include Independent Non-Executive Director at SOPHiA GENETICS SA since 2014, Director at FoRx Therapeutics AG since 2019, Partner at NeoMed S.à.r.l.
since 2017, Partner at Omega Fund Management LLC since 2014, and Member of the Supervisory Board at Immunic AG.
Former jobs include Director at Lifespan, Inc., RainDance Technologies, Inc., Vital Therapies, Inc., Andrew Alliance SA, Luxe Trading SA, eTheRNA immunotherapies NV, Aerium Therapeutics, Inc., and Omega Funds; Independent Director at BioInvent International AB and Immunic, Inc. from 2016 to 2023; Director at Kuros Biosciences Ltd. from 2015 to 2016; Co-Manager at Pictet - Biotech; Investment Manager at Sectoral Asset Management, Inc. (Switzerland) from 2010 to 2013; Partner & Financial Advisor at Covalence SA (Switzerland); and Research Analyst at Pictet Bank & Trust Ltd. (Private Banking).
Education includes graduate and doctorate degrees from the University of Geneva.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 18/03/2026 | 503.136 ( 0,7% ) | 3 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SOPHIA GENETICS SA | Direttore/Membro del Consiglio | 01/06/2014 |
NeoMed S.à.r.l.
NeoMed S.à.r.l. Investment ManagersFinance Functions as an alternative investment manager | Investitore di Private Equity | 01/01/2017 |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Direttore/Membro del Consiglio | 01/10/2019 |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Direttore/Membro del Consiglio | - |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management invests in private and public companies located in the US and Europe. The firm focuses on sectors such as biotechnology, life sciences, healthcare and medical devices. It provides financing for seed, early, mid and later stage capital requirements. It makes direct secondary investments along with follow-on investments. | Investitore di Private Equity | 01/01/2014 |
| Società | Posizione | Fine |
|---|---|---|
| IMMUNIC, INC. | Direttore/Membro del Consiglio | 28/06/2023 |
| KUROS BIOSCIENCES AG | Direttore/Membro del Consiglio | 01/05/2016 |
Sectoral Asset Management, Inc. (Switzerland)
Sectoral Asset Management, Inc. (Switzerland) Investment ManagersFinance Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research. The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it. Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets. Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation. | Direttore/Membro del Consiglio | 01/01/2013 |
Omega Funds
Omega Funds Investment Trusts/Mutual FundsMiscellaneous Open-End Investment Fund/Unit Trust | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ ░ ░░░░░░░░░░░ | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 22 |
|---|---|
Lifespan, Inc.
Lifespan, Inc. Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
RainDance Technologies, Inc.
RainDance Technologies, Inc. Medical SpecialtiesHealth Technology Develops and commercializes professional laboratory system | Health Technology |
Omega Funds
Omega Funds Investment Trusts/Mutual FundsMiscellaneous Open-End Investment Fund/Unit Trust | Miscellaneous |
Pictet - Biotech
Pictet - Biotech Investment Trusts/Mutual FundsMiscellaneous Acts as Open-End Investment Fund/Unit Trust | Miscellaneous |
BioInvent International AB
BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotherapeutic company focused on developing a cell-based therapy | Health Technology |
University of Geneva
University of Geneva Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NeoMed S.à.r.l.
NeoMed S.à.r.l. Investment ManagersFinance Functions as an alternative investment manager | Finance |
Sectoral Asset Management, Inc. (Switzerland)
Sectoral Asset Management, Inc. (Switzerland) Investment ManagersFinance Sectoral is a fundamentals-based, medium- to long-term, GARP-oriented manager which focuses on companies in the healthcare (Pharmaceuticals, Generics, Biotechs and Medtechs) sector. They aim to achieve superior returns for investors by concentrating on primary research. The firm conducts preliminary research and analysis, including literature and documentation, interaction with companies and with Sectoral's Advisory Network, to identify investment candidates. They then conduct forecasting and scenario analyses, testing a range of assumptions and success factors critical to the company's success. They subsequently generate realistic valuation ranges for potential investments and assess the impact of the investment on the overall risk/return profile of the portfolio. They believe that specific risk is the most important risk component and have developed and refined their investment process to mitigate it. Their analysts attempt to determine the fair value for investment candidates as well as 1-year and 3-year price targets. Depending on the development stage of the company, they utilize models such as discounted cash-flow models, EBITDA models, classical growth models (PE approach), enterprise value/sales and peer group analysis to determine the price targets. Sectoral makes recommendations based on the resulting fair value to the current market value of each investment candidate and constructs portfolios comprised of analysts' investment recommendations. Their CIO determines the weight of each industry based on the attractiveness of expected growth, profitability, historic valuation and relative valuation. | Finance |
Covalence SA (Switzerland)
Covalence SA (Switzerland) Investment ManagersFinance Provides investment research | Finance |
Omega Fund Management LLC
Omega Fund Management LLC Investment ManagersFinance Omega Fund Management invests in private and public companies located in the US and Europe. The firm focuses on sectors such as biotechnology, life sciences, healthcare and medical devices. It provides financing for seed, early, mid and later stage capital requirements. It makes direct secondary investments along with follow-on investments. | Finance |
Pictet Bank & Trust Ltd. (Private Banking)
Pictet Bank & Trust Ltd. (Private Banking) Investment ManagersFinance Profile Unavailable. | Finance |
SOPHiA GENETICS SA
SOPHiA GENETICS SA Packaged SoftwareTechnology Services Develops software services for healthcare industry | Technology Services |
Kuros Biosciences Ltd.
Kuros Biosciences Ltd. BiotechnologyHealth Technology Develops biological products for tissue repair | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Develops novel immunotherapies to overcome cancers and infectious diseases | Health Technology |
Andrew Alliance SA
Andrew Alliance SA Industrial MachineryProducer Manufacturing Develops and markets novel liquid handling robots to enhance the reproducibility and the efficiency of the pipetting process | Producer Manufacturing |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals in the immunology space | Health Technology |
Immunic, Inc.
Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
FoRx Therapeutics AG
FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology Develops cancer treatment compounds | Health Technology |
Omega Alpha SPAC
Omega Alpha SPAC Financial ConglomeratesFinance Operates as a blank check company | Finance |
Luxe Trading SA | |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery & development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale